The CAPN3 p.Lys 254del variant is not always associated with dominant CAPN3-related muscular dystrophy.

CANP3 LGMDD4 LGMDR1 calpain 3, dominant inheritance pattern camptocormia

Journal

Muscle & nerve
ISSN: 1097-4598
Titre abrégé: Muscle Nerve
Pays: United States
ID NLM: 7803146

Informations de publication

Date de publication:
01 Feb 2024
Historique:
revised: 09 01 2024
received: 25 05 2023
accepted: 14 01 2024
medline: 1 2 2024
pubmed: 1 2 2024
entrez: 1 2 2024
Statut: aheadofprint

Résumé

Limb-girdle muscular dystrophy R1 (LGMDR1) calpain 3-related usually presents as a recessively transmitted weakness of proximal limb-girdle muscles due to pathogenic variants in the CAPN3 gene. Pathogenic variants in this gene have also been found in patients with an autosomal dominantly inherited transmission pattern (LGMDD4). The mechanism underlying this difference in transmission patterns has not yet been elucidated. Camptocormia, progressive limb weakness, myalgia, back pain, and increased CK levels are common clinical features associated with dominant forms. The p.Lys254del pathogenic variant was associated with camptocormia in two LGMDD4 families. This study aimed to present carriers found in recessively transmitted LGMDR1 families bearing the p.Lys254del variant that do not show muscle weakness. DNA sequencing was performed on exon 5 of CAPN3 in family members to establish the carrier status of the pathogenic variant. They were evaluated clinically and MRI was performed when available. Two families presented with the p.Lys254del pathogenic variant in a homozygous or compound heterozygous state. Family members carrying only the pathogenic variant in the heterozygous state did not demonstrate the myopathic characteristics described in dominant patients. Camptocormia and other severe clinical symptoms were not observed. We conclude that the p.Lys254del pathogenic variant per se cannot be solely responsible for camptocormia in dominant patients. Other undisclosed factors may regulate the phenotype associated with the dominant inheritance pattern in CAPN3 pathogenic variant carriers.

Identifiants

pubmed: 38299438
doi: 10.1002/mus.28045
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Instituto de Salud Carlos III (ISCIII), co-funded by the European Union
ID : PI21/00047
Organisme : Department of Health of the Government of the Basque Country
ID : 2021111022
Organisme : Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED)
ID : CB06/05/1126
Organisme : GENE (Association of Neuromuscular diseases of Gipuzkoa)

Informations de copyright

© 2024 The Authors. Muscle & Nerve published by Wiley Periodicals LLC.

Références

Urtasun M, Sáenz A, Roudaut C, et al. Limb-girdle muscular dystrophy in Guipuzcoa (Basque Country, Spain). Brain. 1998;121:1735-1747. doi:10.1093/brain/121.9.1735
Fardeau M, Hillaire D, Mignard C, et al. Juvenile limb-girdle muscular dystrophy clinical, histopathological and genetic data from a small community living in the Reunion Island. Brain. 1996;119:295-308. doi:10.1093/brain/119.1.295
Richard I, Broux O, Allamand V, et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell. 1995;81:27-40. doi:10.1016/0092-8674(95)90368-2
Sorimachi H, Imajoh-Ohmi S, Emori Y, et al. Molecular cloning of a novel mammalian calcium-dependent protease distinct from both m- and μ-types. Specific expression of the mRNA in skeletal muscle. J Biol Chem. 1989;264:20106-20111. doi:10.1016/S0021-9258(19)47225-6
Liewluck T, Goodman BP. Late-onset axial myopathy and camptocormia in a calpainopathy carrier. J Clin Neuromuscul Dis. 2012;13:209-213. doi:10.1097/CND.0b013e3182461a9c
Vissing J, Barresi R, Witting N, et al. A heterozygous 21-bp deletion in CAPN3 causes dominantly inherited limb girdle muscular dystrophy. Brain. 2016;139:2154-2163. doi:10.1093/brain/aww133
Martinez-Thompson JM, Niu Z, Tracy JA, et al. Autosomal dominant calpainopathy due to heterozygous CAPN3 C.643_663del21. Muscle Nerve. 2018;57:679-683. doi:10.1002/mus.25970
Nallamilli BRR, Chakravorty S, Kesari A, et al. Genetic landscape and novel disease mechanisms from a large LGMD cohort of 4656 patients. Ann Clin Transl Neurol. 2018;5:1574-1587. doi:10.1002/acn3.649
Cerino M, Bartoli M, Riccardi F, et al. Autosomal dominant segregation of CAPN3 c.598_612del15 associated with a mild form of calpainopathy. Ann Clin Transl Neurol. 2020;7:2538-2540. doi:10.1002/acn3.51193
Cerino M, Campana-Salort E, Salvi A, et al. Novel CAPN3 variant associated with an autosomal dominant calpainopathy. Neuropathol Appl Neurobiol. 2020;46:564-578. doi:10.1111/nan.12624
González-Mera L, Ravenscroft G, Cabrera-Serrano M, et al. Heterozygous CAPN3 missense variants causing autosomal-dominant calpainopathy in seven unrelated families. Neuropathol Appl Neurobiol. 2021;47:283-296. doi:10.1111/nan.12663
Vissing J, Dahlqvist JR, Roudaut C, et al. A single c.1715G>C calpain 3 gene variant causes dominant calpainopathy with loss of calpain 3 expression and activity. Hum Mutat. 2020;41:1507-1513. doi:10.1002/humu.24066
Spinazzi M, Poupiot J, Cassereau J, et al. Late-onset camptocormia caused by a heterozygous in-frame CAPN3 deletion. Neuromuscul Disord. 2021;31:450-455. doi:10.1016/j.nmd.2021.02.012
Blázquez L, Azpitarte M, Sáenz A, et al. Characterization of novel CAPN3 isoforms in white blood cells: an alternative approach for limb-girdle muscular dystrophy 2A diagnosis. Neurogenetics. 2008;9:173-182. doi:10.1007/s10048-008-0129-1
Fischer D, Kley RA, Strach K, et al. Distinct muscle imaging patterns in myofibrillar myopathies. Neurology. 2008;71:758-765. doi:10.1212/01.wnl.0000324927.28817.9b
Hackman P, Vihola A, Haravuori H, et al. Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the gene encoding the giant skeletal-muscle protein titin. Am J Hum Genet. 2002;71:240-248. doi:10.1086/342380
Hackman JPV, Vihola AK, Udd AB. The role of titin in muscular disorders. Ann Med. 2003;35:434-441. doi:10.1080/07853890310012797
Udd B, Vihola A, Sarparanta J, Richard I, Hackman P. Titinopathies and extension of the M-line mutation phenotype beyond distal myopathy and LGMD2J. Neurology. 2005;64:636-642. doi:10.1212/01.WNL.0000151853.50144.82
Klein A, Lillis S, Munteanu I, et al. Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies. Hum Mutat. 2012;33:981-988. doi:10.1002/humu.22056
Snoeck M, van Engelen BGM, Küsters B, et al. RYR1-related myopathies: a wide spectrum of phenotypes throughout life. Eur J Neurol. 2015;22:1094-1112. doi:10.1111/ene.12713
Ben Hamida M, Fardeau M, Attia N. Severe childhood muscular dystrophy affecting both sexes and frequent in Tunisia. Muscle Nerve. 1983;6:469-480. doi:10.1002/mus.880060702
Fischer D, Aurino S, Nigro V, Schröder R. On symptomatic heterozygous alpha-sarcoglycan gene mutation carriers. Ann Neurol. 2003;54:674-678. doi:10.1002/ana.10738
Illa I, De Luna N, Domínguez-Perles R, et al. Symptomatic dysferlin gene mutation carriers: characterization of two cases. Neurology. 2007;68:1284-1289. doi:10.1212/01.wnl.0000256768.79353.60

Auteurs

Andrea Valls (A)

Neurosciences Area, Biodonostia Health Research Institute, San Sebastian, Spain.
CIBERNED, CIBER, Spanish Ministry of Science & Innovation, Carlos III Health Institute, Madrid, Spain.

Gerardo Gutiérrez-Gutiérrez (G)

CIBERNED, CIBER, Spanish Ministry of Science & Innovation, Carlos III Health Institute, Madrid, Spain.
Department of Neurology, Hospital Universitario Infanta Sofía, Madrid, Spain.
Neuromuscular Diseases Unit, Universidad Europea de Madrid, Madrid, Spain.

Agustín Martínez (A)

Hospital Público da Mariña-Burela, Burela, Spain.

Cristina Ruiz-Roldán (C)

Neurosciences Area, Biodonostia Health Research Institute, San Sebastian, Spain.
CIBERNED, CIBER, Spanish Ministry of Science & Innovation, Carlos III Health Institute, Madrid, Spain.

Pilar Camaño (P)

Neurosciences Area, Biodonostia Health Research Institute, San Sebastian, Spain.
CIBERNED, CIBER, Spanish Ministry of Science & Innovation, Carlos III Health Institute, Madrid, Spain.
Molecular Diagnostics Platform, Biodonostia Health Research Institute, San Sebastian, Spain.

Adolfo López de Munain (A)

Neurosciences Area, Biodonostia Health Research Institute, San Sebastian, Spain.
CIBERNED, CIBER, Spanish Ministry of Science & Innovation, Carlos III Health Institute, Madrid, Spain.
Department of Neurology, Donostialdea Integrated Health Organisation, Osakidetza, San Sebastian, Spain.
Department of Neurosciences, University of the Basque Country UPV-EHU, San Sebastian, Spain.
Faculty of Medicine, University of Deusto, Bilbao, Spain.

Amets Sáenz (A)

Neurosciences Area, Biodonostia Health Research Institute, San Sebastian, Spain.
CIBERNED, CIBER, Spanish Ministry of Science & Innovation, Carlos III Health Institute, Madrid, Spain.

Classifications MeSH